Prescribing information and adverse events reporting can be found at the end of this email.
This email is intended for healthcare professionals only.
|
|
|
|
|
|
|
|
|
As COVID-19 care becomes incorporated into daily practice, we recognise that managing hospitalised patients at high-risk of COVID-19 progression remains an important issue in the treatment landscape. Join our multidisciplinary faculty for interactive, case-based discussions on patients hospitalised for and with COVID-19, and for insights on implementing consistent and optimal care management between different disciplines. Through a comprehensive overview of the evidence for antiviral treatment in the hospital setting, we will discuss how to apply these data in everyday practice.
We hope you are able to join us for what promises to be an engaging and informative session.
|
|
|
|
|
|
|
|
|
Prof. Andrew Ustianowski
|
Prof. Veronika Müller
|
Prof. Nicola Montano
|
Dr Roger
Paredes
|
North Manchester General Hospital Manchester,
United Kingdom
|
Semmelweis University, Budapest,
Hungary
|
University of Milan, Milan,
Italy
|
Hospital Universitari
Germans Trias i Pujol
Catalonia,
Spain
|
|
|
|
|
|
|
|
|
|
|
16:00-16:10
|
|
Welcome and introduction
|
|
Dr Christine Kelly
(ESCMID-appointed chair) &
Prof. Andrew Ustianowski (Chair)
|
|
|
16:10-16:30
|
|
Test and assess: How are we identifying
patients with COVID-19?
|
|
Dr Roger Paredes
|
|
|
16:30-16:45
|
|
Patient care pathway:
Perspectives from internal medicine
|
|
Prof. Nicola Montano;
All panel to discuss
|
|
|
16:45-17:00
|
|
Patient care pathway: Perspectives from
an infectious disease physician
|
|
Dr Roger Paredes;
All panel to discuss
|
|
|
17:00-17:15
|
|
Patient care pathway:
Perspectives from a pulmonologist
|
|
Prof. Veronika Müller;
All panel to discuss
|
|
|
17:15-17:30
|
|
Audience Q&A
|
|
Moderated by
Dr Christine Kelly &
Prof. Andrew Ustianowski
|
|
|
|
|
|
|
|
This is a promotional initiative organised and fully funded by Gilead Sciences Europe Ltd. It is intended for healthcare professionals only and will include discussion of Gilead products.
Full prescribing information for VEKLURY▼ (remdesivir) in Europe is available here: www.ema.europa.eu/en/medicines/human/EPAR/veklury.
Full prescribing information for VEKLURY® ▼ (remdesivir) in Northern Ireland & Ireland is available here: www.emcpi.com/pi/ni/423.
Full prescribing information for VEKLURY® ▼ in England, Scotland and Wales is available here: www.emcpi.com/pi/38228.
▼ This medicinal product is currently subject to additional monitoring, as indicated by the presence of the inverted black triangle.
Adverse events should be reported to Gilead safety and to your national reporting system.
|
|
|
|
Adverse events should be reported. For Great Britain and Northern Ireland, reporting forms and information can be found at coronavirus-yellowcard.mhra.gov.uk or via the Yellow Card app (downloaded from the Apple App Store or Google Play Store). Adverse events should also be reported to Gilead to safety_FC@gilead.com
|
|
Adverse events should be reported. For Ireland, reporting forms and information can be found at www.hpra.ie and can be reported to HPRA on +353 1 6764971. Adverse events should also be reported to Gilead to safety_FC@gilead.com or +44 (0) 1223 897500.
|
|
|
|
|
Adverse events should be reported. For Spain, adverse events should be reported to Gilead safety_FC@gilead.com or through the QR code:
|
|
|
|
|
|
|
IHQ-VKY-0484 | Date of preparation: March 2024
|
|
|
You have received this email as a contact of ESCMID or one of its affiliated societies.
You can unsubscribe here.
|
|
|
|
|
